EED and cancer: Moreover, EEDi-5285 is the most potent EED inhibitor that has been reported, and it achieves complete and long-lasting tumor regression in mice, further suggesting great potential for the treatment of PRC2-dependent cancers by inhibiting the EED-H3K27me3 interaction [279].